NASDAQ:RPTX Repare Therapeutics (RPTX) Stock Forecast, Price & News $12.70 +0.51 (+4.18%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$12.00▼$12.7650-Day Range$8.16▼$13.0152-Week Range$8.02▼$18.68Volume310,297 shsAverage Volume114,521 shsMarket Capitalization$534.54 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Repare Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside65.4% Upside$21.00 Price TargetShort InterestBearish3.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.45) to ($3.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector686th out of 963 stocksPharmaceutical Preparations Industry309th out of 448 stocks 3.4 Analyst's Opinion Consensus RatingRepare Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Repare Therapeutics has a forecasted upside of 65.4% from its current price of $12.70.Amount of Analyst CoverageRepare Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.77% of the float of Repare Therapeutics has been sold short.Short Interest Ratio / Days to CoverRepare Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Repare Therapeutics has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRepare Therapeutics does not currently pay a dividend.Dividend GrowthRepare Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPTX. Previous Next 2.2 News and Social Media Coverage News SentimentRepare Therapeutics has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Repare Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for RPTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Repare Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repare Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.50% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Repare Therapeutics are expected to decrease in the coming year, from ($2.45) to ($3.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repare Therapeutics is -84.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repare Therapeutics is -84.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRepare Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Repare Therapeutics (NASDAQ:RPTX) StockRepare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.Read More RPTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPTX Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comRepare Therapeutics (NASDAQ:RPTX) Price Target Increased to $17.00 by Analysts at Stifel NicolausSeptember 26, 2023 | americanbankingnews.comRepare Therapeutics (NASDAQ:RPTX) Shares Gap Up on Analyst UpgradeSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 25, 2023 | msn.comStifel Maintains Repare Therapeutics (RPTX) Buy RecommendationSeptember 20, 2023 | finance.yahoo.comStrength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?September 19, 2023 | finance.yahoo.comRepare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 6, 2023 | finance.yahoo.comRepare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 16, 2023 | finance.yahoo.comWall Street Thinks This Cathie Wood Stock Could Jump by 187%September 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 14, 2023 | finance.yahoo.comBrokers Are Upgrading Their Views On Repare Therapeutics Inc. (NASDAQ:RPTX) With These New ForecastsAugust 10, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Their Buy Rating for Repare Therapeutics (RPTX)August 9, 2023 | finance.yahoo.comRepare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue EstimatesAugust 9, 2023 | finance.yahoo.comRepare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsJuly 16, 2023 | finance.yahoo.comRepare Therapeutics (NASDAQ:RPTX) shareholders have endured a 52% loss from investing in the stock three years agoJuly 8, 2023 | fool.comRepare Therapeutics (NASDAQ: RPTX)June 11, 2023 | markets.businessinsider.comRepare Therapeutics (RPTX) Receives a Buy from Bloom BurtonJune 9, 2023 | msn.comHC Wainwright & Co. Maintains Repare Therapeutics (RPTX) Buy RecommendationJune 9, 2023 | msn.comStifel Upgrades Repare Therapeutics (RPTX)June 8, 2023 | finance.yahoo.comRepare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 8, 2023 | markets.businessinsider.comRepare Therapeutics (RPTX) Receives a Buy from Berenberg BankJune 8, 2023 | markets.businessinsider.comRepare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination TrialsJune 6, 2023 | finance.yahoo.comRepare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid TumorsJune 5, 2023 | finance.yahoo.comRepare Therapeutics Inc.'s (NASDAQ:RPTX) market cap touched US$481m last week, benefiting both private equity firms who own 34% as well as institutionsJune 2, 2023 | finance.yahoo.comRepare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials InsightsMay 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)May 22, 2023 | finance.yahoo.comRepare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 17, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Repare Therapeutics (RPTX)See More Headlines Receive RPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RPTX Company Calendar Last Earnings8/09/2023Today9/26/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RPTX CUSIPN/A CIK1808158 Webwww.reparerx.com Phone857-412-7018FaxN/AEmployees180Year Founded2016Price Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$28.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+63.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,050,000.00 Net Margins-1.85% Pretax Margin11.23% Return on Equity-1.14% Return on Assets-0.87% Debt Debt-to-Equity RatioN/A Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$131.83 million Price / Sales4.05 Cash FlowN/A Price / Cash FlowN/A Book Value$6.66 per share Price / Book1.91Miscellaneous Outstanding Shares42,090,000Free Float30,097,000Market Cap$534.54 million OptionableNot Optionable Beta0.02 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Lloyd Mitchell Segal (Age 59)Pres, CEO & Director Comp: $913.39kDr. Michael Zinda Ph.D. (Age 52)Exec. VP & Chief Scientific Officer Comp: $641.53kDr. Maria Koehler M.D. (Age 66)Ph.D., Exec. VP & Chief Medical Officer Comp: $682.8kDr. Daniel Durocher Ph.D.Co-FounderDr. Frank Sicheri Ph.D.Co-FounderDr. Agnel Sfeir Ph.D.Co-FounderMr. Steve Forte (Age 44)Exec. VP & CFO Mr. Daniel BelangerExec. VP of Human ResourceMr. Cameron BlackExec. VP of DiscoveryDr. Kim A. Seth Ph.D.Exec. VP & Chief Bus. OfficerMore ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPHEntrada TherapeuticsNASDAQ:TRDAIntercept PharmaceuticalsNASDAQ:ICPT23andMeNASDAQ:MEZymeworksNYSE:ZYMEView All CompetitorsInsiders & InstitutionsBarclays PLCBought 3,409 shares on 9/21/2023Ownership: 0.008%Goldman Sachs Group Inc.Sold 11,993 shares on 8/15/2023Ownership: 0.154%XTX Topco LtdSold 26,793 shares on 8/15/2023Ownership: 0.052%Citadel Advisors LLCSold 1,300 shares on 8/15/2023Ownership: 0.000%Geode Capital Management LLCBought 5,347 shares on 8/11/2023Ownership: 0.076%View All Insider TransactionsView All Institutional Transactions RPTX Stock - Frequently Asked Questions Should I buy or sell Repare Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RPTX shares. View RPTX analyst ratings or view top-rated stocks. What is Repare Therapeutics' stock price forecast for 2023? 4 brokerages have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price forecasts range from $14.00 to $28.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 65.4% from the stock's current price. View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts. How have RPTX shares performed in 2023? Repare Therapeutics' stock was trading at $14.71 at the beginning of the year. Since then, RPTX stock has decreased by 13.7% and is now trading at $12.70. View the best growth stocks for 2023 here. When is Repare Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our RPTX earnings forecast. How were Repare Therapeutics' earnings last quarter? Repare Therapeutics Inc. (NASDAQ:RPTX) announced its earnings results on Wednesday, August, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.55. The company had revenue of $30.25 million for the quarter, compared to the consensus estimate of $7.28 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 1.14% and a negative net margin of 1.85%. What ETF holds Repare Therapeutics' stock ? ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio. What other stocks do shareholders of Repare Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AmerisourceBergen (ABC), AES (AES), Autodesk (ADSK) and When did Repare Therapeutics IPO? (RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO. What is Repare Therapeutics' stock symbol? Repare Therapeutics trades on the NASDAQ under the ticker symbol "RPTX." Who are Repare Therapeutics' major shareholders? Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (6.29%), ARK Investment Management LLC (6.24%), Sumitomo Mitsui Trust Holdings Inc. (0.77%), BlackRock Inc. (0.74%), Renaissance Technologies LLC (0.35%) and Bank of Montreal Can (0.28%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley. View institutional ownership trends. How do I buy shares of Repare Therapeutics? Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Repare Therapeutics' stock price today? One share of RPTX stock can currently be purchased for approximately $12.70. How much money does Repare Therapeutics make? Repare Therapeutics (NASDAQ:RPTX) has a market capitalization of $534.54 million and generates $131.83 million in revenue each year. The company earns $-29,050,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. How many employees does Repare Therapeutics have? The company employs 180 workers across the globe. How can I contact Repare Therapeutics? Repare Therapeutics' mailing address is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. The official website for the company is www.reparerx.com. The company can be reached via phone at 857-412-7018 or via email at investor@reparerx.com. This page (NASDAQ:RPTX) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.